← Leaderboards
Carlo M Croce
Thomas Jefferson University
$37,904,390
Attributed
$43,053,471
Total exposure
25
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.8M · FY2006–21$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$74,568,041 · 30
By mechanism
P01$25,778,530 · 13
R01$16,536,195 · 9
P30$14,892,506 · 3
R35$6,360,184 · 1
U01$6,290,078 · 2
RC2$4,057,634 · 1
Top collaborators
- Ramiro Garzon5 shared
- Guido Marcucci5 shared
- Serge P Nana-Sinkam5 shared
- Harvey Ira Pass5 shared
Most similar at Thomas Jefferson University
Same institution · by research overlap
- John Eisenbrey$7,634,263
- Harris Goldstein$29,313,609
- Ronald E Myers$9,443,300
- Ronald Allen Coss$1,099,963
- Andrea C Morrione$2,229,925
Others in their field
Top investigators on “Micrornas”
- Stacey Gabriel · Broad Institute, Inc.$30,965,067
- Stuart L Schreiber · Harvard University (Medical School)$30,193,983
- Charles M Perou · Univ Of North Carolina Chapel Hill$21,050,635
- Frank J. Slack · Beth Israel Deaconess Medical Center$20,540,036
- David A Bennett · Rush University Medical Center$20,460,113
- Richard M Myers · Hudson-Alpha Institute For Biotechnology$19,845,919
Research focus
MicrornasGenesMalignant NeoplasmsTumor Suppressor GenesBaseCellsOncogenesPathogenesisMolecular ProfilingChronic Lymphocytic LeukemiaProteinsMutationNeoplasm /Cancer GeneticsGene ExpressionPathway InteractionsTumorLeukemiaOverexpressionMalignant - DescriptorResearch PersonnelProgramsMalignant Neoplasm Of LungGeneticApoptosis
Grant awards (134)
Cancer Gene Discovery to Identify Targetable Targets$843,904
R35 · FY2021 · CA · contact PI
Cancer Gene Discovery to Identify Targetable Targets$924,000
R35 · FY2020 · CA · contact PI
Biologic and Therapeutic Significance of miR-155 in AML$528,129
R01 · FY2020 · CA
Cancer Gene Discovery to Identify Targetable Targets$896,280
R35 · FY2019 · CA · contact PI
Biologic and Therapeutic Significance of miR-155 in AML$515,834
R01 · FY2019 · CA
Molecular Mechanisms of Cachexia in Lung Cancer$416,213
R01 · FY2019 · CA · contact PI
Cancer Gene Discovery to Identify Targetable Targets$924,000
R35 · FY2018 · CA · contact PI
Biologic and Therapeutic Significance of miR-155 in AML$549,553
R01 · FY2018 · CA
Molecular Mechanisms of Cachexia in Lung Cancer$429,084
R01 · FY2018 · CA · contact PI
Cancer Gene Discovery to Identify Targetable Targets$924,000
R35 · FY2017 · CA · contact PI
Identifying non-coding RNAs for early detection and prevention of lung cancer$915,659
U01 · FY2017 · CA · contact PI
Biologic and Therapeutic Significance of miR-155 in AML$554,107
R01 · FY2017 · CA
Molecular Mechanisms of Cachexia in Lung Cancer$429,084
R01 · FY2017 · CA · contact PI
Cancer Gene Discovery to Identify Targetable Targets$924,000
R35 · FY2016 · CA · contact PI
Identifying non-coding RNAs for early detection and prevention of lung cancer$897,104
U01 · FY2016 · CA · contact PI
Biologic and Therapeutic Significance of miR-155 in AML$574,050
R01 · FY2016 · CA
Molecular Genetics$434,909
P01 · FY2016 · CA · contact PI
Molecular Mechanisms of Cachexia in Lung Cancer$429,084
R01 · FY2016 · CA · contact PI
Cancer Gene Discovery to Identify Targetable Targets$924,000
R35 · FY2015 · CA · contact PI
Identifying non-coding RNAs for early detection and prevention of lung cancer$905,221
U01 · FY2015 · CA · contact PI
Molecular Genetics$533,439
P01 · FY2015 · CA · contact PI
Molecular Mechanisms of Cachexia in Lung Cancer$429,084
R01 · FY2015 · CA · contact PI
Microarray$173,539
P30 · FY2015 · CA · contact PI
TOWARD AN UNDERSTANDING OF CLL PROGRESSION$34,752
R01 · FY2015 · CA · contact PI
Identifying non-coding RNAs for early detection and prevention of lung cancer$851,643
U01 · FY2014 · CA · contact PI
Molecular Genetics$528,163
P01 · FY2014 · CA · contact PI
TOWARD AN UNDERSTANDING OF CLL PROGRESSION$363,375
R01 · FY2014 · CA · contact PI
MiRNAs/UCRs: biomarkers for cancer risk, tumor detection, progression & treatment$344,369
U01 · FY2014 · CA · contact PI
Microarray$168,786
P30 · FY2014 · CA · contact PI
Identifying non-coding RNAs for early detection and prevention of lung cancer$967,089
U01 · FY2013 · CA · contact PI
Role of 11q23 Chromosome Abnormalities in the Causation of Acute Leukemia$877,670
P01 · FY2013 · CA · contact PI
Molecular Genetics$521,506
P01 · FY2013 · CA · contact PI
MicroRNAs as Targets for the Treatment of Hepatocellular Carcinoma$484,324
R01 · FY2013 · CA · contact PI
TOWARD AN UNDERSTANDING OF CLL PROGRESSION$352,327
R01 · FY2013 · CA · contact PI
MiRNAs/UCRs: biomarkers for cancer risk, tumor detection, progression & treatment$333,718
U01 · FY2013 · CA · contact PI
Microarray$162,697
P30 · FY2013 · CA · contact PI
Role of ALL-1 Fusion Proteins in microRNA Biogenesis$127,016
P01 · FY2013 · CA · contact PI
Administration/Program Operations, and Biostatistics Data Mgt. & Array Analyses$82,480
P01 · FY2013 · CA · contact PI
Role of 11q23 Chromosome Abnormalities in the Causation of Acute Leukemia$937,343
P01 · FY2012 · CA · contact PI
Molecular Genetics$558,342
P01 · FY2012 · CA · contact PI
MicroRNAs as Targets for the Treatment of Hepatocellular Carcinoma$516,062
R01 · FY2012 · CA · contact PI
TOWARD AN UNDERSTANDING OF CLL PROGRESSION$375,020
R01 · FY2012 · CA · contact PI
MiRNAs/UCRs: biomarkers for cancer risk, tumor detection, progression & treatment$354,255
U01 · FY2012 · CA · contact PI
Role of miR155 in Leukemogenesis$301,148
R01 · FY2012 · CA · contact PI
Microarray$174,008
P30 · FY2012 · CA · contact PI
Role of ALL-1 Fusion Proteins in microRNA Biogenesis$135,421
P01 · FY2012 · CA · contact PI
Administration/Program Operations, and Biostatistics Data Mgt. & Array Analyses$88,088
P01 · FY2012 · CA · contact PI
Role of 11q23 Chromosome Abnormalities in the Causation of Acute Leukemia$940,999
P01 · FY2011 · CA · contact PI
MicroRNAs as Targets for the Treatment of Hepatocellular Carcinoma$516,908
R01 · FY2011 · CA · contact PI
TOWARD AN UNDERSTANDING OF CLL PROGRESSION$375,231
R01 · FY2011 · CA · contact PI
MiRNAs/UCRs: biomarkers for cancer risk, tumor detection, progression & treatment$355,020
U01 · FY2011 · CA · contact PI
Role of miR155 in Leukemogenesis$301,992
R01 · FY2011 · CA · contact PI
MicroRNA"s in the Treatment of AML$291,254
P01 · FY2011 · CA · contact PI
FHIT Gene Therapy in Cancer Prevention and Treatment$221,160
R01 · FY2011 · CA · contact PI
Role of ALL-1 Fusion Proteins in microRNA Biogenesis$135,731
P01 · FY2011 · CA · contact PI
Administration/Program Operations, and Biostatistics Data Mgt. & Array Analyses$88,438
P01 · FY2011 · CA · contact PI
Loss of miR-29s as predictor of response to demethylating agents$2,026,079
RC2 · FY2010 · CA · contact PI
Role of 11q23 Chromosome Abnormalities in the Causation of Acute Leukemia$973,478
P01 · FY2010 · CA · contact PI
Molecular Genetics of CLL$586,428
P01 · FY2010 · CA · contact PI
MicroRNAs as Targets for the Treatment of Hepatocellular Carcinoma$480,411
R01 · FY2010 · CA · contact PI
MiRNAs/UCRs: biomarkers for cancer risk, tumor detection, progression & treatment$366,000
U01 · FY2010 · CA · contact PI
Role of miR155 in Leukemogenesis$336,489
R01 · FY2010 · CA · contact PI
ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri$313,613
R01 · FY2010 · CA · contact PI
MicroRNA"s in the Treatment of AML$301,442
P01 · FY2010 · CA · contact PI
FHIT Gene Therapy in Cancer Prevention and Treatment$228,000
R01 · FY2010 · CA · contact PI
Role of ALL-1 Fusion Proteins in microRNA Biogenesis$140,245
P01 · FY2010 · CA · contact PI
Administration/Program Operations, and Biostatistics Data Mgt. & Array Analyses$91,537
P01 · FY2010 · CA · contact PI
Loss of miR-29s as predictor of response to demethylating agents$2,031,555
RC2 · FY2009 · CA · contact PI
Role of 11q23 Chromosome Abnormalities in the Causation of Acute Leukemia$1,011,385
P01 · FY2009 · CA · contact PI
Molecular Genetics of CLL$576,406
P01 · FY2009 · CA · contact PI
MicroRNAs as Targets for the Treatment of Hepatocellular Carcinoma$519,141
R01 · FY2009 · CA · contact PI
Role of miR155 in Leukemogenesis$330,797
R01 · FY2009 · CA · contact PI
ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri$308,345
R01 · FY2009 · CA · contact PI
MicroRNA"s in the Treatment of AML$296,496
P01 · FY2009 · CA · contact PI
FHIT Gene Therapy in Cancer Prevention and Treatment$228,000
R01 · FY2009 · CA · contact PI
Role of ALL-1 Fusion Proteins in microRNA Biogenesis$137,968
P01 · FY2009 · CA · contact PI
Administration/Program Operations, and Biostatistics Data Mgt. & Array Analyses$90,211
P01 · FY2009 · CA · contact PI
Role of miR155 in Leukemogenesis$547,067
R01 · FY2008 · CA · contact PI
Molecular Genetics of CLL$545,602
P01 · FY2008 · CA · contact PI
ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri$300,246
R01 · FY2008 · CA · contact PI
MicroRNA"s in the Treatment of AML$294,594
P01 · FY2008 · CA · contact PI
FHIT Gene Therapy in Cancer Prevention and Treatment$228,000
R01 · FY2008 · CA · contact PI
Molecular Genetics of CLL$541,785
P01 · FY2007 · CA · contact PI
ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri$298,169
R01 · FY2007 · CA · contact PI
MicroRNA"s in the Treatment of AML$290,900
P01 · FY2007 · CA · contact PI
FHIT Gene Therapy in Cancer Prevention and Treatment$228,000
R01 · FY2007 · CA · contact PI
Molecular Genetics of CLL$399,189
P01 · FY2006 · CA · contact PI
ALL Fusion Proteins: Associated with Multi-protein Complexes and Role in Transcri$298,467
R01 · FY2006 · CA · contact PI
ONCOGENES IN CANCER ETIOLOGY AND PROGRESSION$820,002
P01 · FY2004 · CA
ONCOGENES IN CANCER ETIOLOGY AND PROGRESSION$362,667
P01 · FY2004 · CA
8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA$338,483
R01 · FY2004 · CA
8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA$104,671
R01 · FY2004 · CA
TRANSLATIONAL RESEARCH IN CANCER$4,827,378
P30 · FY2003 · CA
ONCOGENE DEREGULATION/TUMOR SUPPRESSOR GENE LOSS IN CLL$1,589,968
P01 · FY2003 · CA
ONCOGENES IN CANCER ETIOLOGY AND PROGRESSION$1,149,341
P01 · FY2003 · CA
8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA$430,353
R01 · FY2003 · CA
TRANSLATIONAL RESEARCH IN CANCER$250,000
P30 · FY2003 · CA
TRANSLATIONAL RESEARCH IN CANCER$4,385,601
P30 · FY2002 · CA
ONCOGENE DEREGULATION/TUMOR SUPPRESSOR GENE LOSS IN CLL$1,544,922
P01 · FY2002 · CA
ONCOGENES IN CANCER ETIOLOGY AND PROGRESSION$1,116,986
P01 · FY2002 · CA
8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA$417,819
R01 · FY2002 · CA
ARP--GENE TARGET OF THE ALL1 GENE IN ACUTE LEUKEMIAS$378,283
R01 · FY2002 · CA
Molecular genetics of CLL$165,355
P01 · FY2002 · CA
Mechanisms of FHIT Gene Fragility in Human Cancers Induced by Carcinogens$151,299
P01 · FY2002 · CA
Oncogene Deregulation in B- and T-Cell Chronic Lymphocytic Leukemia$0
P01 · FY2002 · CA
GENETICS OF KAPOSI'S SARCOMA--ROLE OF THE FHIT GENE$0
P01 · FY2002 · CA
Structure /Function of All-1 Complexes--Normal /Leukemic$0
P01 · FY2002 · CA
TRANSLATIONAL RESEARCH IN CANCER$4,220,081
P30 · FY2001 · CA
ONCOGENE DEREGULATION/TUMOR SUPPRESSOR GENE LOSS IN CLL$1,501,186
P01 · FY2001 · CA
ONCOGENES IN CANCER ETIOLOGY AND PROGRESSION$1,085,565
P01 · FY2001 · CA
8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA$405,649
R01 · FY2001 · CA
ARP--GENE TARGET OF THE ALL1 GENE IN ACUTE LEUKEMIAS$367,941
R01 · FY2001 · CA
TRAINING PROGRAM IN MOLECULAR GENETICS OF CANCER$315,089
T32 · FY2001 · CA
Molecular genetics of CLL$165,355
P01 · FY2001 · CA
Mechanisms of FHIT Gene Fragility in Human Cancers Induced by Carcinogens$151,299
P01 · FY2001 · CA
Role of BCL2 phosphorylation in Cancer Chemotherapy$76,744
P01 · FY2001 · CA
GENETICS OF KAPOSI'S SARCOMA--ROLE OF THE FHIT GENE$0
P01 · FY2001 · CA
Molecular genetics of CLL$0
P01 · FY2001 · CA
Oncogene Deregulation in B- and T-Cell Chronic Lymphocytic Leukemia$0
P01 · FY2001 · CA
Structure /Function of All-1 Complexes--Normal /Leukemic$0
P01 · FY2001 · CA
Molecular genetics of CLL$0
P01 · FY2001 · CA
ONCOGENE DEREGULATION/TUMOR SUPPRESSOR GENE LOSS IN CLL$1,458,739
P01 · FY2000 · CA
ONCOGENES IN CANCER ETIOLOGY AND PROGRESSION$1,106,271
P01 · FY2000 · CA
8P22 ALTERATIONS, IN PROSTATE, BREAST AND ESOPHAGEAL CA$393,833
R01 · FY2000 · CA
ARP--GENE TARGET OF THE ALL1 GENE IN ACUTE LEUKEMIAS$357,897
R01 · FY2000 · CA
TRAINING PROGRAM IN MOLECULAR GENETICS OF CANCER$337,825
T32 · FY2000 · CA
CORE--DEVELOPMENTAL FUNDS$279,549
P30 · FY2000 · CA
Oncogene Deregulation in B- and T-Cell Chronic Lymphocytic Leukemia$258,493
P01 · FY2000 · CA
TRANSLATIONAL RESEARCH IN CANCER$250,867
P30 · FY2000 · CA
Role of BCL2 phosphorylation in Cancer Chemotherapy$210,505
P01 · FY2000 · CA
GENETICS OF KAPOSI'S SARCOMA--ROLE OF THE FHIT GENE$154,069
P01 · FY2000 · CA
Mechanisms of FHIT Gene Fragility in Human Cancers Induced by Carcinogens$151,299
P01 · FY2000 · CA
Molecular genetics of CLL$0
P01 · FY2000 · CA
Structure /Function of All-1 Complexes--Normal /Leukemic$0
P01 · FY2000 · CA